{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kokabi N"],"funding":["Radiological Society of North America","NCI NIH HHS","Sirtex Medical Ltd"],"pagination":["1743-1752"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10119065"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["50(6)"],"pubmed_abstract":["<h4>Background</h4>There is an increasing body of evidence indicating Y90 dose thresholds for tumor response and treatment-related toxicity. These thresholds are poorly studied in resin Y90, particularly in hepatocellular carcinoma (HCC).<h4>Purpose</h4>To evaluate the efficacy of prospective voxel-based dosimetry for predicting treatment response and adverse events (AEs) in patients with HCC undergoing resin-based Y90 radioembolization.<h4>Materials and methods</h4>This correlative study was based on a prospective single-arm clinical trial (NCT04172714), which evaluated the efficacy of low/scout (555 MBq) activity of resin-based Y90 for treatment planning. Partition model was used with goal of tumor dose (TD) > 200 Gy and non-tumoral liver dose (NTLD) < 70 Gy for non-segmental therapies. "],"journal":["European journal of nuclear medicine and molecular imaging"],"pubmed_title":["Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study."],"pmcid":["PMC10119065"],"funding_grant_id":["P30 CA008748","Investigator Initiated Study","Research Scholar Grant"],"pubmed_authors":["Arndt-Webster L","Bercu Z","Davarpanahfakhr A","Kokabi N","Kappadath SC","Brandon D","Schuster DM","Elsayed M","Chen B","Galt J","Sethi I","Cristescu M"],"additional_accession":[]},"is_claimable":false,"name":"Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.","description":"<h4>Background</h4>There is an increasing body of evidence indicating Y90 dose thresholds for tumor response and treatment-related toxicity. These thresholds are poorly studied in resin Y90, particularly in hepatocellular carcinoma (HCC).<h4>Purpose</h4>To evaluate the efficacy of prospective voxel-based dosimetry for predicting treatment response and adverse events (AEs) in patients with HCC undergoing resin-based Y90 radioembolization.<h4>Materials and methods</h4>This correlative study was based on a prospective single-arm clinical trial (NCT04172714), which evaluated the efficacy of low/scout (555 MBq) activity of resin-based Y90 for treatment planning. Partition model was used with goal of tumor dose (TD) > 200 Gy and non-tumoral liver dose (NTLD) < 70 Gy for non-segmental therapies. ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 May","modification":"2025-04-04T10:22:26.407Z","creation":"2025-02-19T02:38:19.472Z"},"accession":"S-EPMC10119065","cross_references":{"pubmed":["36650357"],"doi":["10.1007/s00259-023-06111-9"]}}